A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions

Hepatic ImpairmentHealthy

Interventions

DRUG

Lazertinib

Lazertinib tablet will be administered orally.

Trial Locations (2)

CRS Clinical Research Services Kiel GmbH, Kiel

APEX GmbH, München

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT05112952 - A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) | Biotech Hunter | Biotech Hunter